Biopharma veteran to advise Sei’s $65m Open Science Fund on scaling decentralized research for longevity, health and biotech.
Sapien Capital, the decentralized science (DeSci) investment arm of the Sei Foundation, has appointed Dr Michael Baran, Partner at Pfizer Ventures, as a strategic advisor. His role will be to shape the investment strategy for the $65 million Open Science Fund I and to guide the growth of Sei’s DeSci vertical – with the stated aim of making the blockchain platform the “infrastructure rails” for the future of scientific collaboration in longevity, biotech and other frontier research domains.
The timing reflects both a maturation and a challenge for DeSci. While early projects have demonstrated proof-of-concept in areas such as decentralized funding, community-led data ownership and tokenized research participation, many have yet to progress to large-scale deployment. Baran’s remit will be to help convert such prototypes into sustainable, operationally robust ventures capable of addressing real bottlenecks in drug development and translational science.
Pfizer, through its venture arm, has already dipped into DeSci with VitaDAO, so Baran’s new advisory role isn’t a random leap, but can be viewed as part of a longer, strategic interest in decentralized science models.
Longevity.Technology: DeSci has long promised to liberate science from the shackles of centralized funding bodies and glacial publication cycles – yet, for all the rhetoric, much of the movement remains mired in proof-of-concept purgatory, with enthusiasm outpacing adoption. The appointment of Michael Baran is therefore more than just another hire – it is a signal that the grown-ups have arrived. Baran brings a track record forged in the pressure cooker of biopharma investment and R&D, and his presence suggests an intent to bridge the gulf between crypto-native ideals and the operational realities of drug development, particularly in longevity where timelines are measured in decades and budgets in billions. If DeSci is to escape its echo chamber and build the institutional-grade systems that can turn molecular hunches into regulatory-approved therapies, then strategic nous of this caliber is non-negotiable.
The lofty goal of flipping Eroom’s Law – making drug discovery faster rather than slower – is a fine rallying cry, but without the rails to support large-scale coordination, transparent funding and interoperable data, it risks becoming just another pretty slogan. Sei’s claim to offer that infrastructure, coupled with Sapien Capital’s longevity-relevant focus, makes this an experiment worth watching closely; it may even be the start of DeSci 2.0, where theory finally meets execution. The longevity sector, with its appetite for frontier science and its chronic underfunding in early-stage translational work, could be an early beneficiary – provided, of course, that the technology delivers on its promises and the community embraces a little less utopianism and a little more pragmatism. If that marriage of vision and practicality holds, we might yet see the kind of collaborative velocity that the aging field has been crying out for.
The right expertise at the right time
Baran’s credentials traverse laboratory bench work, clinical development and high-stakes investment decision-making. At Pfizer Ventures and in his capacity as Executive Director of Worldwide Business Development, Baran has navigated both scientific and commercial terrain from the vantage point of a strategic investor. His adjunct professorship in biomedical engineering at Stony Brook University reflects an academic grounding that complements his industry remit, while his track record in steering high-stakes investment decisions gives him a clear view of the operational realities DeSci projects must meet if they are to attract institutional partners and achieve regulatory clearance.
For Sapien Capital’s Global DeSci Lead, Eleanor Davies, Baran’s arrival is part of a deliberate strategy to move the sector beyond its insular beginnings. “Michael has an unmatched perspective that will contribute to the scalability and institutional adoption of DeSci,” she said. “We’re here to build beyond the bubble, and realize the full potential that crypto has in the sciences.”
Davies added that Baran’s involvement aligns with the organization’s view that DeSci is entering a second phase of development. “His experience in the industry, and as a DeSci advocate from day one, makes him the ideal partner for success in the DeSci V2 on Sei. We’re still early, and there’s a lot of potential. We’re thrilled to welcome him into the fold as we make Sei the go-to destination for DeSci and frontier technologies.”
Infrastructure for longevity research
The Sei Foundation’s blockchain is positioned as a high-performance platform capable of supporting the computational and coordination requirements of scientific research at scale. This includes not only the capital formation and governance mechanisms for early-stage R&D but also the integration of distributed datasets, transparent ownership frameworks and smart-contract-driven collaboration models.
Speaking to Longevity.Technology, Eleanor Davies described longevity research as being faced with “a Gordian knot of inefficiencies across the drug development spectrum – from capital formation and talent coordination to accessing clinical trial data and ensuring quality management is consistent and well audited. It can take decades to bring therapeutics to patients, and we don’t have time for this.” DeSci models, she argued, are beginning to address these issues, with projects such as VitaDAO demonstrating the potential of decentralized collaboration.
For longevity research – often a casualty of fragmented funding channels, prolonged development timelines and siloed data – such capabilities could be transformative. Whether the task is harmonizing multi-omics datasets from global cohorts, aligning AI-driven target discovery with real-world clinical data, or enabling rapid funding decisions for translational projects, the ability to coordinate resources and knowledge across borders could help reduce duplication, accelerate validation and improve capital efficiency.
“The Open Science Fund is reducing the barriers to entry, particularly in underfunded fields such as longevity,” Davies explained. “We’re making it possible for the under-resourced yet overly online entrepreneurs across the globe to gain access to funding, a high caliber ecosystem and to accelerate the field.” She added that Sei’s architecture “handles exactly what the field demands: fast finality for real-time milestone funding, parallel processing for handling massive aging datasets, and permissionless coordination so a computational biologist at one end of the globe can collaborate with a clinician at the other, at internet speed – not institutional pace.”
Baran’s own statement reflected this ambition. “Science moves at the speed of collaboration, but our infrastructure hasn’t caught up,” he said. “Sei represents the first blockchain capable of supporting the computational demands and coordination requirements that research actually needs. There’s a huge opportunity to expedite the sciences that simply wasn’t feasible before.”
Momentum or mirage
DeSci remains, in many ways, an experiment – one that must now prove it can scale without losing the openness and inclusivity that attracted its early adherents. The addition of seasoned industry figures such as Baran could help temper some of the sector’s more speculative tendencies while preserving its capacity for innovation. For longevity science, which often pushes into poorly charted biological territory, the combination of stable infrastructure and strategic capital may prove a timely advantage.
In search of the tipping point
If DeSci is to contribute meaningfully to the acceleration of longevity research, it must evolve from an intriguing adjunct to a trusted part of the scientific apparatus. Whether that tipping point comes through the adoption of Sei’s infrastructure, the influence of figures like Baran, or the slow accumulation of successful case studies remains to be seen – but the momentum is building, and the sector will not be short of willing observers.
